No Prescription |
 |
 | ||
|
Prescription Drugs 4 |
|
| ||
No Prescription » Prescription Drugs 4
Catapres TTS 1 Generic Clonidine Catapres TTS 2 Generic Clonidine Catapres TTS 3 Generic Clonidine Cellcept Generic Mycophenolate Mofetil Champix Maintenance Pack Chantix Chlorsig Eye Drops Generic Chloramphenicol Chlorsig Eye Oint Generic Chloramphenicol Climara Generic Estradiol transdermal system Climen Generic Estradiol 17 valerat Climodien Generic Estradiol valerate Clopivas A Plavix with Aspirin Colchicum Dispert Generic Colchicine Colgout Tabs Generic Colchicine Combantrin Generic Pyrantel embonate Combigan Generic Brimonidine Tartrate Timolol Maleate
No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
|
|
|